Monge O R, Rofstad E K, Kaalhus O
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Eur J Cancer Clin Oncol. 1988 Oct;24(10):1661-9. doi: 10.1016/0277-5379(88)90060-0.
The interaction between water bath hyperthermia (43.5 degrees C) and six cancer chemotherapeutic agents in vivo was studied in a transplantable C3H mouse mammary carcinoma grown s.c. in the feet of C3D2F1/Bom mice. Due to differences in tumour regrowth rate between treatment groups, both tumour growth time (TGT) and specific growth delay (SGD) were used as effect parameters. The largest tumour response was observed when the drug was given 15 min prior to heat--this timing was used for dose-effect experiments. Enhancement ratios were the ratios of slopes of dose-effect curves subjected to linear regression analysis. The drug enhancement ratio (DER) was not significantly larger than 1.0 for LD 1% of adriamycin, 5-fluorouracil, methotrexate and vincristine. For cyclophosphamide (CTX) and mitomycin C (MMC) both DER and TER (thermal enhancement ratio) were significantly larger than 1.0. The TGT ratios (SGD ratios in parentheses) were: DER (LD 1%): CTX 1.4 +/- 0.1 (2.1 +/- 0.1), MMC 1.3 +/- 0.1 (1.4 +/- 0.1); TER (43.5 degrees C 30 min): CTX 1.6 +/- 0.1 (2.7 +/- 0.2), MMC 2.8 +/- 0.5 (3.3 +/- 0.7). The data support the choice of CTX and MMC in preference to the other drugs investigated for clinical thermochemotherapy studies.
在可移植到C3D2F1/Bom小鼠足部皮下生长的C3H小鼠乳腺癌模型中，研究了43.5℃水浴热疗与六种癌症化疗药物在体内的相互作用。由于各治疗组肿瘤再生长速率存在差异，将肿瘤生长时间（TGT）和特定生长延迟（SGD）均用作效应参数。当在热疗前15分钟给药时，观察到最大的肿瘤反应——该给药时间用于剂量效应实验。增强比是进行线性回归分析的剂量效应曲线斜率之比。对于阿霉素、5-氟尿嘧啶、甲氨蝶呤和长春新碱的1%致死剂量，药物增强比（DER）并不显著大于1.0。对于环磷酰胺（CTX）和丝裂霉素C（MMC），DER和热增强比（TER）均显著大于1.0。TGT比（括号内为SGD比）为：DER（1%致死剂量）：CTX 1.4±0.1（2.1±0.1），MMC 1.3±0.1（1.4±0.1）；TER（43.5℃，30分钟）：CTX 1.6±0.1（2.7±0.2），MMC 2.8±0.5（3.3±0.7）。这些数据支持在临床热化疗研究中优先选择CTX和MMC而非所研究的其他药物。
